Skip to main content

Animations

MJFF Publications

461 - 470 of 6422 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2021
  • 2022
  • 2022
  • 2021
  • 2022
  • Summary Details
    OPEN
    Title: Beta amyloid deposition and cognitive decline in Parkinson’s disease: a study of the PPMI cohort
    Journal Name: Molecular Brain
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s13041-022-00964-1
    Citation Count: 33
  • Summary Details
    OPEN
    Title: Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration
    Journal Name: Nature Communications
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41467-022-32944-3
    Citation Count: 43
  • Summary Details
    OPEN
    Title: Interpretable deep learning of myelin histopathology in age-related cognitive impairment
    Journal Name: Acta Neuropathologica Communications
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s40478-022-01425-5
    Citation Count: 28
  • Summary Details
    OPEN
    Title: Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity
    Journal Name: Nature Neuroscience
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41593-022-01140-3
    Citation Count: 172
  • Summary Details
    OPEN
    Title: The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II
    Journal Name: Frontiers in Neurology
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fneur.2022.994114
    Citation Count: 4
  • Summary Details
    OPEN
    Title: Lower Circulating Lymphocyte Count Predicts ApoEε4‐Related Cognitive Decline in Parkinson's Disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/mds.28799
    Citation Count: 14
  • Summary Details
    OPEN
    Title: Adenosine A2A Receptor Occupancy by Caffeine After Coffee Intake in Parkinson's Disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/mds.28897
    Citation Count: 19
  • Summary Details
    OPEN
    Title: Altered Cholinergic Innervation in De Novo Parkinson's Disease with and Without Cognitive Impairment
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/mds.28913
    Citation Count: 61
  • Summary Details
    OPEN
    Title: The Myelin‐Weighted Connectome in Parkinson's Disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1002/mds.28891
    Citation Count: 33
  • Summary Details
    OPEN
    Title: A Randomized, Double‐Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/mds.28970
    Citation Count: 31
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.